Alnylam, Medtronic, CHDI Foundation Inc. neurology, drug delivery news

Not-for-profit CHDI agreed to initially fund up to 50% of IND-enabling activities for ALN-HTT, a preclinical Huntington's disease (HD) candidate from Alnylam and Medtronic. The foundation said the amount of funding would be in excess of $10 million. ALN-HTT is an siRNA against the huntingtin gene delivered to the CNS via Medtronic's implantable pump infusion system. ...